Sanofi: Information concerning the total number of voting rights and shares - November 2023 Information concerning the total number of voting...
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes Availability of the Q4 2023 Memorandum for modelling purposes...
Communiqué de presse : L’EMA a rendu un avis favorable pour le Fexinidazole Winthrop comme premier traitement oral de la forme aigüe...
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics Statement on FTC challenge to proposed...
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible...
CP : L’essai de phase III consacré au Sarclisa® (isatuximab) a atteint son critère d’évaluation primaire de survie sans progression chez des...
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to...
Communiqué de presse : Dupixent® a permis de réduire significativement les exacerbations de BPCO dans le cadre d’un second essai positif de...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.